Drug intelligence / Profile preview

AcinetoVax

Development stage: Preclinical
Lead developer: Vaxdyn
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal, Intramuscular

Overview

AcinetoVax is a monovalent vaccine candidate developed by Vaxdyn to prevent infections caused by antibiotic-resistant *Acinetobacter baumannii*. The vaccine is designed to elicit a protective immune response by targeting specific outer membrane proteins (OMPs) of the bacterium. *A. baumannii* is a major cause of hospital-acquired infections, particularly in intensive care units, and is frequently resistant to multiple classes of antibiotics, including carbapenems. By targeting conserved surface proteins, AcinetoVax aims to provide broad protection against various clinical isolates of this pathogen. It is currently in the preclinical stage of development.

Other names: Acinetobacter baumannii vaccine

Targets

OmpA (Outer membrane protein A)

Beyond the preview

Go deeper on AcinetoVax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AcinetoVax.

Explore the full profile